Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Allogene (Nasdaq: ALLO) will present interim futility analysis data from its pivotal, randomized Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.
The company will host a live conference call and webcast at 5:30 a.m. PT / 8:30 a.m. ET; the webcast will be available under the Investors / News and Events section at the company website.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – ALLO
+12.50%
28 alerts
+12.50%News Effect
+16.9%Peak Tracked
-5.8%Trough Tracked
+$75MValuation Impact
$677.70MMarket Cap
0.8xRel. Volume
On the day this news was published, ALLO gained 12.50%, reflecting a significant positive market reaction.
Argus tracked a peak move of +16.9% during that session.
Argus tracked a trough of -5.8% from its starting point during tracking.
Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility.
This price movement added approximately $75M to the company's valuation, bringing the market cap to $677.70M at that time.
Trial phasePhase 2Pivotal ALPHA3 trial of cema-cel in 1L consolidation LBCL
Interim analysis typeInterim futility analysisPivotal Phase 2 ALPHA3 trial readout to be discussed
Conference call dateApril 13, 2026Scheduled date to review ALPHA3 interim futility analysis
Call time PT5:30 a.m. PTStart time of conference call and webcast
Call time ET8:30 a.m. ETStart time of conference call and webcast
Price move7.78%Same-day move ahead of ALPHA3 interim futility analysis call
52-week range$0.8621 – $2.91Current price sits at the top of the 52-week range
Market cap$658,200,384Equity value prior to ALPHA3 futility analysis data discussion
Market Reality Check
Price:$2.05Vol:Volume 4,786,121 is below...
normal vol
$2.05Last Close
VolumeVolume 4,786,121 is below the 20-day average of 5,695,901, suggesting the 7.78% move came without outsized trading activity.normal
TechnicalAt $2.91, shares match the 52-week high and trade above the $1.52 200-day moving average, reflecting strength into the ALPHA3 interim readout.
Peers on Argus
ALLO gained 7.78% while peers showed mixed moves: IVVD up 28.06%, CADL down 1.64...
ALLO gained 7.78% while peers showed mixed moves: IVVD up 28.06%, CADL down 1.64%, NMRA down 3.7%, with RAPT and VNDA nearly flat. No peers appeared in the momentum scanner, pointing to a stock-specific reaction.
Activation of first community cancer centers for pivotal ALPHA3 cema-cel trial.
Pattern Detected
Clinical and trial-related updates have produced mixed outcomes: strong late-stage or mature data often aligned with sizeable gains, while earlier-stage or preclinical updates sometimes coincided with negative price reactions.
Recent Company History
Over the past two years, Allogene has steadily advanced its allogeneic CAR T pipeline, with multiple clinical trial milestones. Phase 1 data for ALLO-316 in RCC and Phase 1 ALPHA/ALPHA2 data for cema‑cel in LBCL showed encouraging response rates and durability, driving notable positive moves on Feb 13, 2025 and Jun 1, 2025. Earlier, activation of ALPHA3 community sites on Jul 1, 2024 and preclinical ALLO‑329 data produced muted or negative reactions. Today’s announcement of an ALPHA3 interim futility analysis call fits into this sequence of increasingly pivotal cema‑cel readouts.
Historical Comparison
+9.4% avg move · In the past 5 clinical-trial updates, ALLO moved an average of 9.4%. The current futility-analysis c...
clinical trial
+9.4%
Average Historical Moveclinical trial
In the past 5 clinical-trial updates, ALLO moved an average of 9.4%. The current futility-analysis call continues a pattern where key data events often drive meaningful stock reactions.
Clinical updates progressed from activating ALPHA3 sites and early ALLO-316/ALLO-329 data to durable Phase 1 cema-cel results, now culminating in a pivotal Phase 2 ALPHA3 interim futility analysis in first-line LBCL.
Market Pulse Summary
The stock surged +12.5% in the session following this news. A strong positive reaction aligns with t...
Analysis
The stock surged +12.5% in the session following this news. A strong positive reaction aligns with the pattern that major clinical inflection points often moved ALLO shares meaningfully, as seen around prior cema‑cel and ALLO‑316 data. Trading at $2.91, matching the 52-week high, into a pivotal ALPHA3 futility analysis underscores expectations for this readout. Investors historically reacted sharply to late‑stage efficacy data, while earlier milestones were mixed, suggesting outcomes and any follow‑on financing or strategic decisions could influence sustainability.
Key Terms
interim futility analysis, pivotal, phase 2, allogeneic car t, +2 more
6 terms
interim futility analysisclinical
"host a conference call and webcast to review the interim futility analysis from its pivotal"
An interim futility analysis is a planned mid-study check of trial results to determine whether a medical study is unlikely to show the expected benefit if it continues. For investors, this matters because a futility finding can lead to stopping the trial early, saving the company money but also reducing the chance of a future product approval and revenue; think of it as a halftime assessment that decides whether continuing the game is worth the cost.
pivotalclinical
"review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial"
Pivotal describes a test, event, or decision that is decisive for whether a product, idea, or plan moves forward—most often used for a late-stage clinical trial or a regulatory review whose result determines approval or rejection. Investors care because a positive outcome typically unlocks major value (like market access or sales), while a negative one can sharply reduce expected future revenue; think of it as the final exam that decides whether a project passes or fails.
phase 2clinical
"interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with"
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
allogeneic car tmedical
"pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer"
Allogeneic CAR T is a type of cancer immunotherapy made from immune cells collected from a healthy donor, genetically reprogrammed to recognize and kill cancer cells, and stored like an off‑the‑shelf medicine. For investors it matters because donor-based products can be manufactured at scale and delivered faster and cheaper than patient-specific (custom) therapies, but they also carry different safety and regulatory risks that affect commercial potential and valuation.
large b-cell lymphomamedical
"cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma"
Large B‑cell lymphoma is a type of fast-growing cancer that starts in B cells, a kind of white blood cell that helps the body fight infection. For investors it matters because the condition drives demand for diagnostics, treatments and clinical trials; positive or negative trial results, regulatory decisions or new therapies can quickly change a biotech or drug maker’s revenue prospects, similar to how a breakthrough product can reshape a company’s future.
lbclmedical
"consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026."
Large B-cell lymphoma (LBCL) is an aggressive form of non-Hodgkin lymphoma in which a type of white blood cell called a B cell grows uncontrollably, forming tumors in lymph nodes and other tissues. For investors, LBCL matters because it defines a clear patient population and urgent medical need, shaping clinical trial priorities, regulatory decisions, drug pricing and the commercial potential for therapies—think of it as a high-priority market segment where treatment breakthroughs can quickly change company valuations.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.
The live conference call and webcast will take place at 5:30 a.m. PT / 8:30 a.m. ET. Please use this link to register. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
When will Allogene (ALLO) discuss the interim futility analysis from the ALPHA3 trial?
Allogene will review the interim futility analysis on April 13, 2026 at 5:30 a.m. PT / 8:30 a.m. ET. According to the company, the data will be presented on a live conference call and webcast and posted under Investors > News and Events on the website.
What is the subject of the interim futility analysis Allogene (ALLO) is presenting for ALPHA3?
The analysis covers cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. According to the company, it is an interim futility review from the pivotal randomized Phase 2 ALPHA3 trial and will be discussed on the webcast.
How can investors access Allogene (ALLO) conference call and webcast for the ALPHA3 update?
Investors can join the live call and webcast by registering via the provided link and watching the webcast on the company website. According to the company, the webcast will be posted under the Investors tab in the News and Events section.
Will Allogene (ALLO) provide trial data details during the April 13, 2026 webcast?
The company will review the interim futility analysis during the live webcast on April 13, 2026. According to the company, the conference call and webcast are intended to present and discuss the interim ALPHA3 trial data for cema-cel in 1L consolidation LBCL.
What trial and indication are covered in Allogene's (ALLO) April 13, 2026 presentation?
The presentation covers the pivotal, randomized Phase 2 ALPHA3 trial of cema-cel in first-line consolidation for large B-cell lymphoma. According to the company, the interim futility analysis from that trial will be the focus of the call and webcast.
